Sanofi and Orano join forces to develop next-generation radioligand medicines Paris, . Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development ...

New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants Paris, . Sanofi advances its ambition to protect ...

If you are a healthcare professional or a patient seeking to report an adverse event, please call 1-800-265-7927 to speak with a Sanofi Medical Information agent or click here to visit Sanofi Medical ...

100% of developing countries work towards the UNFCCC goal of having their NAPs in place by 2025, with all new NAPs including specific health targets reflecting national and sub-national priorities.

Paris, France – September 26, 2024. Sanofi announced today that its Q3 2024 Aide mémoire is available on the "Investors" page of the company's website: As for each quarter, Sanofi prepared this ...

Parfois, l’innovation technologique peut provenir d’espace inattendus. Dans le développement de médicaments, cela signifie souvent l’intersection de technologies apparemment sans rapport ou de ...

100 % des pays en développement œuvrent pour atteindre l'objectif de la CCNUCC d'avoir leurs PNA (Plans nationaux d'adaptation) en place d'ici 2025, avec l'inclusion dans chaque nouveau PNA ...

Paris, France, le 26 Septembre 2024. Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Q3 2024 Aide mémoire ». Résultats du troisième ...

Sanofi’s commitment to society is long-term, and a longstanding legacy. Our commitment translates into a set of actions to make a positive impact on the lives of people and communities around the ...

Communiqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d ...

Third quarter 2024 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session. Third quarter 2025 results will ...

헬스케어 분야에서 미충족 수요가 있는 곳에 교육 및 의약품 접근성 향상, 질환인식개선을 위해 노력합니다. 이를 위해 환자를 Care하며, 건강을 Protect하고, 사회를 Engage하는 사회책임활동을 ...